Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ME Therapeutics HoldingFRA:Q9T 14 3-Year RORE % is -54.27 as of May. 2026. GuruFocus rates FRA:Q9T with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,296 Biotechnology companies, ME Therapeutics Holding ranks worse than 81.25% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
ME Therapeutics Holding's 3-Year RORE % for the quarter that ended in May. 2026 was -54.27%.
The industry rank for ME Therapeutics Holding's 3-Year RORE % or its related term are showing as below:
FRA:Q9T's 3-Year RORE % is ranked worse than 81.25% of 1296
companies
in the Biotechnology industry
Industry Median: -11.185
vs FRA:Q9T: -54.27
ME Therapeutics Holding (FRA:Q9T) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
ME Therapeutics Holding 3-Year RORE % Related Terms
ME Therapeutics Holding 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:Q9T vs VRTX, REGN, RVMD: 3-Year RORE % Comparison
For the Biotechnology subindustry, ME Therapeutics Holding's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ME Therapeutics Holding 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where ME Therapeutics Holding's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in May. 2026 and 3-year before.
ME Therapeutics Holding (FRA:Q9T) has a 3-Year RORE % of -54.27 as of May. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on ME Therapeutics Holding and its competitors. According to the industry distribution chart, ME Therapeutics Holding ranks #1053 out of 1296 companies in the Biotechnology industry, placing it in the top 81.2%.
Is ME Therapeutics Holding's 3-Year RORE % too high?
ME Therapeutics Holding's current 3-Year RORE % is -54.27. Based on the distribution chart, ME Therapeutics Holding ranks #1053 out of 1296 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ME Therapeutics Holding has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does ME Therapeutics Holding's 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ME Therapeutics Holding ranks #1053 out of 1296 companies for 3-Year RORE %. This places ME Therapeutics Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on ME Therapeutics Holding and its competitors. ME Therapeutics Holding's current 3-Year RORE % is -54.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ME Therapeutics Holding stock overvalued right now?
ME Therapeutics Holding (FRA:Q9T) has a current 3-Year RORE % of -54.27. The current 3-Year RORE % is -54.27. ME Therapeutics Holding's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For ME Therapeutics Holding (FRA:Q9T), the current 3-Year RORE % is -54.27 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ME Therapeutics Holding Inc is a preclinical stage biotechnology company working on cancer-fighting drugs in the field of Immuno Oncology, developing next-generation therapeutics targeting immune suppression in cancer. It is developing novel drugs that target myeloid cells to directly treat cancer and enhance the benefits of current Immuno Oncology drugs, such as checkpoint inhibitors in currently untreatable cancers. Immuno Oncology is a new area of cancer research that has been successful in treating previously untreatable cancers by targeting the immune system rather than the cancer directly, allowing a single drug to be used for multiple cancer types with mostly manageable side effects.
14GF Score
Get the complete analysis for FRA:Q9T
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:Q9T has been successfully added to your 
